GlassScriptPhysician profile
John David Cowden
NPI 1982665071
$6,720.65
in general payments reported to CMS, 2019-2025
14 companies · $2,388 in 2025
The $2,388 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $393 · 2021: $29.42 · 2022: $1,734 · 2023: $980 · 2024: $1,040 · 2025: $2,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,349 · Food and Beverage: $1,336 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,348.53 |
| Food and Beverage | $1,335.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Education | $223.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,547.39 | 2022-2025 | Da Vinci Surgical System |
| Pulmonx Corporation | $248.97 | 2019-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.83 | 2020-2024 | Ofev |
| United Therapeutics Corporation | $156.15 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.29 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $111.94 | 2024-2025 | Winrevair, Zerbaxa |
| Boston Scientific Corporation | $69.70 | 2019 | |
| Mylan Specialty L.P. | $63.57 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $35.10 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $26.71 | 2025 | Uptravi, Opsumit |
| Gilead Sciences, INC. | $25.60 | 2021-2022 | |
| Grifols USA, LLC | $24.93 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.83 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cowden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.